ライフサイエンスコーパス: POTS

1 POTS and NCS differ in tonic cardiac sympathetic functio

2 POTS may be associated with increased limb blood flow ("

3 oneal muscle sympathetic nerve activity in 9 POTS patients and 9 control subjects at rest and during

4 with female control subjects (p < 0.05) and POTS patients (p < 0.001).

5 tudy addressed whether patients with COI and POTS or NCS have neurocirculatory abnormalities during s

6 Volume-pressure relations of controls and POTS patients with normal P(v) and high P(v) were not di

7 ic and asymptomatic groups within the OH and POTS groups.

8 Because POTS and NCS both include specific abnormalities of card

9 Disorder Treatment Study for Young Children [POTS Jr]) conducted at 3 academic medical centers betwee

10 (MSN) discharge characteristics in 12 female POTS patients and in 9 male and 12 female control subjec

11 A subgroup of low-flow POTS patients had exaggerated venoconstriction to phenyl

12 ) combined with iontophoresis in 15 low-flow POTS patients, 17 normal-flow POTS patients, and 13 heal

13 rn of thermal hyperemia response in low-flow POTS subjects during saline administration resembled the

14 which was insensitive to L-NAME in low-flow POTS subjects.

15 ycardia syndrome (POTS), designated low-flow POTS, is associated with decreased peripheral blood flow

16 eous vasoregulation was similar for low-flow POTS, normal-flow POTS, and reference subjects.

17 decreased peripheral blood flow in low-flow POTS, we performed experiments using laser-Doppler flowm

18 nitric oxide release is reduced in low-flow POTS.

19 in 15 low-flow POTS patients, 17 normal-flow POTS patients, and 13 healthy reference volunteers varyi

20 n was similar for low-flow POTS, normal-flow POTS, and reference subjects.

21 ction were analyzed in skin fibroblasts from POTS and compared with control cells.

22 Adult patients referred for COI who had POTS (n=90, mean+/-SEM age 40+/-1 years, 86% women) or N

23 stent with increased sympathetic activity in POTS and did not change in response to hypotension.

24 ion to the increase in total MSN activity in POTS patients compared with female control subjects, and

25 tion was shifted toward larger amplitudes in POTS patients (p < 0.005), consistent with increased sym

26 ency result in normal or even elevated BP in POTS patients.

27 ts (p < 0.001), whereas it did not change in POTS patients.

28 Venous compliance in POTS is similar to that in control subjects.

29 results from increased venous compliance in POTS patients.

30 Supine Pv was not different in POTS, but upright leg Pv tended to be increased above co

31 o the total activity increase was greater in POTS patients than in female (p < 0.05) and male (p < 0.

32 es orthostatic tolerance and hemodynamics in POTS.

33 and heart rate were significantly higher in POTS patients than in controls.

34 A lower SV resulted in a higher HR in POTS at any given oxygen uptake (V(O(2))) during exercis

35 Autonomic function was intact in POTS patients.

36 and mRNA expression were 2-3 times lower in POTS fibroblasts, and choline uptake was reduced 60% (P

37 V(O(2peak)) was lower in POTS than controls (26.1 +/- 1.0 (SEM) vs. 36.3 +/- 0.9

38 ed sympathetic outflow significantly more in POTS patients than in controls despite a similar BP decr

39 ting diastolic function was mostly normal in POTS before training, though diastolic suction was impai

40 ulatory control during exercise is normal in POTS; and (b) that physical 'reconditioning' with exerci

41 The findings suggest that pooling in POTS is due to blunted arterial vasoconstriction, which

42 At rest, the burst frequency was similar in POTS patients and controls (18.1+/-6.2 and 20.1+/-7.9 bu

43 Mean cardiac norepinephrine spillover in POTS (171+/-30 pmol/min, N=16) was higher and in NCS (62

44 ociated with a reduced stroke volume (SV) in POTS, and that the high heart rate (HR) observed at rest

45 enuated tachycardia and improved symptoms in POTS.

46 ay contribute to the relative tachycardia in POTS.

47 tion significantly attenuated tachycardia in POTS.

48 neural activity and orthostatic tolerance in POTS women.

49 After training in POTS, HR became lower at any given due to increased SV w

50 lates blood pressure and vasoconstriction in POTS women during orthostatic stress.

51 lates blood pressure and vasoconstriction in POTS women during tilting.

52 Ten of 19 patients no longer met POTS criteria after training, whereas patient quality of

53 ay play a key role in the pathophysiology of POTS.

54 predisposition to and greater prevalence of POTS in female individuals.

55 It seems reasonable to offer POTS a new name based on its underlying pathophysiology,

56 Overall, POTS features increased heart rate and sympathetic nervo

57 Twenty-seven POTS patients underwent autonomic function tests, cardia

58 OI) occurs in postural tachycardia syndrome (POTS) and in some individuals with repeated neurocardiog

59 In postural tachycardia syndrome (POTS) and repeated neurocardiogenic presyncope (NCS), or

60 e postural orthostatic tachycardia syndrome (POTS) and that exercise training improves this syndrome.

61 e postural orthostatic tachycardia syndrome (POTS) are primarily premenopausal women, which may be at

62 Patients with postural tachycardia syndrome (POTS) experience considerable disability, but in most, t

63 Postural tachycardia syndrome (POTS) induces disabling chronic orthostatic intolerance

64 Postural tachycardia syndrome (POTS) induces disabling chronic orthostatic intolerance

65 Postural tachycardia syndrome (POTS) is characterized by excessive orthostatic tachycar

66 Postural tachycardia syndrome (POTS) is related to defective peripheral vasoconstrictio

67 e postural orthostatic tachycardia syndrome (POTS) report fluctuations in orthostatic tolerance throu

68 racterized by postural tachycardia syndrome (POTS) with exaggerated tachycardia, orthostatic symptoms

69 ne variant of postural tachycardia syndrome (POTS), designated low-flow POTS, is associated with decr

70 tension (OH), postural tachycardia syndrome (POTS), or normal HUT groups.

71 e postural orthostatic tachycardia syndrome (POTS), similar to physical deconditioning.

72 h postural orthostatic tachycardia syndrome (POTS), who presented with low plasma choline and betaine

73 olerance with postural tachycardia syndrome (POTS).

74 ents with the postural tachycardia syndrome (POTS).

75 Ten POTS women were studied during the early follicular (EF)

76 The POTS group also had higher mean arterial norepinephrine

77 The POTS group had a relatively fast mean heart rate (79+/-2

78 The POTS group was divided into patients with high venous pr

79 The characteristics of the POTS fibroblasts described here represent a first model

80 earm vascular resistance (52+/-6 U) than the POTS group (36+/-2 U, P=0.003).

81 When POTS cells were treated with choline, transporter was up

82 udied 12 patients 13 to 19 years of age with POTS and defective leg vasoconstriction and 13 age-match

83 ng of sympathetic fiber loss associated with POTS, may contribute to the predisposition to and greate

84 ow level of aldosterone in the patients with POTS (190+/-140 pmol/L versus 380+/-230 pmol/L; P=0.017)

85 g/kg per minute) for 1 hour in patients with POTS (n=15) and healthy controls (n=13) in the supine po

86 Patients with POTS (n=15) and healthy controls (n=14) underwent invest

87 METHODS AND In protocol 1, patients with POTS (n=54) underwent acute drug trials of propranolol 2

88 gic antagonist, esmolol, in 14 patients with POTS aged 13 to 19 years.

89 odium excretion was similar in patients with POTS and controls (-49+/-12 versus -60+/-16 mEq/g creati

90 Ages were similar for patients with POTS and controls (mean+/-SEM, 30+/-2 versus 26+/-1 year

91 ely tested the hypothesis that patients with POTS are hypovolemic compared with healthy controls and

92 re asymptomatic during HUT and patients with POTS are more likely to be symptomatic than patients wit

93 ly increased in the forearm in patients with POTS but was increased in the calf (9.3+/-2.2 versus 5.7

94 upine and upright positions in patients with POTS compared with control subjects (P=0.01, upright leg

95 ine was significantly lower in patients with POTS compared with controls (10.1+/-1.2 versus 16.8+/-1.

96 esponses to Ang II infusion in patients with POTS compared with healthy controls.

97 n response to Ang II infusion, patients with POTS had a blunted increase compared with controls in me

98 Patients with POTS had a greater deficit in plasma volume (334+/-187 v

99 Patients with POTS had a higher orthostatic increase in HR than contro

100 Patients with POTS had symptoms more frequently than patients with OH

101 Patients with POTS have blunted vasopressor response to Ang II and imp

102 We have previously found that patients with POTS have increases in plasma angiotensin II (Ang II) th

103 Patients with POTS have marked increases in heart rate during orthosta

104 Patients with POTS have paradoxically unchanged plasma renin activity

105 Patients with POTS or NCS underwent measurements of neurochemical indi

106 Seventeen patients with POTS underwent acute drug trials of pyridostigmine 30 mg

107 In protocol 2, 18 patients with POTS underwent similar trials of high-dose (80 mg) versu

108 ilarly with Ang II infusion in patients with POTS versus controls (-166+/-20 versus -181+/-17 mL/min

109 s for enhanced leg swelling in patients with POTS with increased arterial blood flow.

110 ite the lower plasma volume in patients with POTS, there was not a compensatory increase in plasma re

111 r responses during exercise in patients with POTS.

112 proves exercise performance in patients with POTS.

113 and improve symptom burden in patients with POTS.

114 and improve symptom burden in patients with POTS.

115 rol across the menstrual cycle in women with POTS are unknown.

116 nce across the menstrual cycle in women with POTS.

117 nce across the menstrual cycle in women with POTS.

118 ardiogenic syncope/presyncope (NCS), without POTS.

119 Nineteen (18 women) POTS patients completed a 3 month training programme.